BOSTON, Sept. 14, 2020 — Lowell Therapeutics, Inc. (LTX), a biopharmaceutical company, announced today that the company has been selected by the M2D2 Center of the University of Massachusetts as a finalist in its annual competition of rising stars in the biotech community. James Wilkie, President & CEO, will provide a corporate overview on Thursday, September 17, 2020 at 6:00 p.m. (EST). You can attend the conference by registering here: http://bit.ly/200KM2D2.
ABOUT THE MASSACHUSETTS MEDICAL DEVICE DEVELOPMENT CENTER (M2D2)
M2D2 is a joint initiative between the campuses of the University of Massachusetts with the aim of helping new biotech and medical device entrepreneurs develop products every step of the way, from proof-of-concept to commercialization. Its affiliated faculty and staff have assisted more than 100 start-up companies and entrepreneurs since the program kicked off in the spring of 2007.
ABOUT LOWELL THERAPEUTICS, INC.
Lowell Therapeutics, Inc. is focused on the discovery, development and commercialization of innovative therapies intended to significantly improve clinical outcomes in critically ill patients. NIYAD™, a late-stage investigational product, is being developed for anticoagulation of the extracorporeal circuit and in particular continuous renal replacement therapy (CRRT).
President & CEO
NIYAD™ is a trademark of Lowell Therapeutics, Inc.